Source - SMW
Futura Medical has recently completed primary market research which indicated that more than 60% of physicians in the US considered that MED2002, the company's novel gel for erectile dysfunction, was an improvement over current ED therapies. 

Futura  said the research, carried out by leading healthcare strategy firm Cello Health Consulting, also revealed that at least 10% of ED patients were contra-indicated to PDE5 inhibitors (such as Viagra or Cialis) because of their existing nitrate medication, a larger percentage than the 7.5% historically stated by the company based on previously conducted research.

 


At 8:17am: (LON:FUM) Futura Medical PLC share price was +1p at 24.5p